Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA panel backs vernakalant

An FDA advisory committee voted 6-2 on Tuesday to recommend approval of vernakalant IV from Astellas (Tokyo:4503)

Read the full 179 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE